ADVA
6.12.2019 09:02:05 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Play has deployed its Oscilloquartz timing solution to provide LTE Advanced services throughout Poland and prepare its network for 5G. The PTP grandmaster with dual integrated GNSS antenna enables Play to deliver the resilient and accurate Precision Time Protocol (PTP) frequency and phase synchronization needed for next-generation connectivity. With its ultra-compact design, the OSA 5405 Series empowers Play to migrate its radio access network from costly GNSS RF antennas and coax cables to standard copper and fiber Ethernet cabling, dramatically reducing capital expenditure and operating expenses. ADVA’s long-term partner NAVI also played a key role in the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005008/en/
“This deployment is about taking our RAN infrastructure to the next level. ADVA’s versatile and compact devices are easy to install in a wide range of outdoor locations. And, with low-touch provisioning and power over Ethernet, installation is even simpler and more cost-effective,” said Michał Ziółkowski, CTO, Play. “This solution delivers the extremely precise timing required for next-generation connectivity. With the OSA 5405 ensuring accurate and robust phase synchronization, we can offer unique LTE Advanced services and prepare for the 5G future.”
Built on the environmentally hardened outdoor variant of the OSA 5405 Series, Play’s new synchronization architecture delivers IP-based frequency and phase synchronization. This ensures ultra-precise timing with no jitter or delay, supporting advanced applications and enhanced user experience. The OSA 5405 Series supports every major GNSS constellation – GPS, BEIDOU, GLONASS and GALILEO – as well as multiple protection options from PTP to SyncE. And, with its compact and environmentally friendly design, it ensures accurate time distribution with the smallest size and power footprint on the market.
“As Poland’s leading mobile communication service provider, it was vital that Play optimized its RAN infrastructure. With our technology ensuring maximum spectral efficiency, Play can provide increased value today and, at the same time, lay down the foundation for the next stage of mobile connectivity,” commented Ardashes Garabedian, senior sales manager, Eastern Europe and CIS, ADVA. “Our easy-to-deploy OSA 5405 Series is the ideal solution to seamlessly and affordably evolve Play’s existing timing architecture to IP-based synchronization. It minimizes complexity and power requirements as well as installation and operating costs. This solution significantly enhances mobile service quality of experience and opens the door to emerging IoT use cases and 5G.”
“Our agile OSA 5405 Series makes the task of bringing precise phase synchronization to the edge of Play’s mobile network simple and cost-efficient. With its ruggedized design and minimal visibility, it can be easily installed in almost any outdoor location,” said Gil Biran, general manager, Oscilloquartz. “Our OSA 5405 Series brings precise sync to built-up areas and urban canyons and, with its low-touch provisioning and plug-and-play features, it ensures straightforward configuration and maximum scale.”
“When it comes to synchronizing packet networks, our engineers offer a wealth of experience and expertise,” said Olaf Frączyk, CTO, NAVI. “We are proud to be part of this network upgrade, helping Play to unleash the full potential of its network. Working closely with our trusted partner ADVA, we’ve created a solution that ensures highly efficient spectrum utilization and unbeatable network performance both now and in years to come.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com
.
About PLAY
PLAY is the leading mobile phone network in Poland, with over 15 million subscribers. The PLAY network is operated by P4 sp. z o.o. whose main shareholder is Play Communications SA – a company listed on the Warsaw Stock Exchange. The company provides mobile voice, text, data and video services to individual and business clients (including, first and foremost, small and medium-sized enterprises), on the basis of contracts or in the pre-paid model, under the PLAY umbrella brand. The services offered by the operator are available to 99% of the Polish population thanks to PLAY’s own, extensive and modern telecommunications network (2G/3G/4G LTE/5G Ready) and the national roaming service. More information can be found at www.playcommunications.com
and www.play.pl
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005008/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
